Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

BACKGROUND: Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of anthracyclines, but in the USA and some European countries, its use had been restr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiooncology
Main Authors: Ganatra, Sarju, Nohria, Anju, Shah, Sachin, Groarke, John D., Sharma, Ajay, Venesy, David, Patten, Richard, Gunturu, Krishna, Zarwan, Corrine, Neilan, Tomas G., Barac, Ana, Hayek, Salim S., Dani, Sourbha, Solanki, Shantanu, Mahmood, Syed Saad, Lipshultz, Steven E.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7048095/
https://ncbi.nlm.nih.gov/pubmed/32154008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-019-0036-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados